Alessandro Vindigni

Alessandro Vindigni

Auto-generated profile, based on publicly available information

Alessandro Vindigni

Division of Oncology, Department of Medicine, Washington University in St. Louis, St. Louis, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2020 in Molecular Cell
Verified
Journal Article
Open access
AQAnnabel Quinet
Annabel Quinet
STStephanie Tirman
Stephanie Tirman
JJJessica Jackson
Jessica Jackson
SŠSaša Šviković
Saša Šviković
DLDelphine Lemaçon
Delphine Lemaçon
AVAlessandro Vindigni
Alessandro Vindigni
Acute treatment with replication-stalling chemotherapeutics causes reversal of replication forks. BRCA proteins protect reversed forks from nucleolytic degradation, and their loss leads to chemosensitivity. Here, we show that fork degradation is no longer detectable in BRCA1-deficient cancer cells exposed to multiple cisplatin doses, mimicking a clinical treatment regimen. This effect depends on increased expression and chromatin loading of PRIMPOL and is regulated by ATR activity. Electron microscopy and single-molecule DNA fiber analyses reveal that PRIMPOL rescues fork degradation by reinitiating DNA synthesis past DNA lesions. PRIMPOL repriming leads to accumulation of ssDNA gaps while suppressing fork reversal. We propose that cells adapt to repeated cisplatin doses by activating PRIMPOL repriming under conditions that would otherwise promote pathological reversed fork degradation. This effect is generalizable to other conditions of impaired fork reversal (e.g., SMARCAL1 loss or PARP inhibition) and suggests a new strategy to modulate cisplatin chemosensitivity by targeting the PRIMPOL pathway.

1 October 2021 in Molecular Cell
Verified
Journal Article
Closed access
STStephanie Tirman
Stephanie Tirman
AQAnnabel Quinet
Annabel Quinet
MWMatthew Wood
Matthew Wood
AMALICE MERONI
ALICE MERONI
ECEmily Cybulla
Emily Cybulla
AVAlessandro Vindigni
Alessandro Vindigni

1 September 2019 in Trends in Cell Biology
Verified
Journal Article
Closed access
ABAndrea K. Byrum
Andrea K. Byrum
AVAlessandro Vindigni
Alessandro Vindigni
NMNima Mosammaparast
Nima Mosammaparast

2 November 2022 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
ECEmily Cybulla
Emily Cybulla
AVAlessandro Vindigni
Alessandro Vindigni

1 February 2021 in Molecular Cell
Verified
Journal Article
Closed access
AQAnnabel Quinet
Annabel Quinet
STStephanie Tirman
Stephanie Tirman
ECEmily Cybulla
Emily Cybulla
AMAlice Meroni
Alice Meroni
AVAlessandro Vindigni
Alessandro Vindigni

28 April 2023 in Science
Verified
Journal Article
Closed access
WLWenpeng Liu
Wenpeng Liu
YSYuichiro Saito
Yuichiro Saito
JJJessica Jackson
Jessica Jackson
RBRahul Bhowmick
Rahul Bhowmick
MKMasato Kanemaki
Masato Kanemaki
DCDavid Cortez
David Cortez
Replication fork reversal safeguards genome integrity as a replication stress response. DNA translocases and the RAD51 recombinase catalyze reversal. However, it remains unknown why RAD51 is required and what happens to the replication machinery during reversal. We find that RAD51 uses its strand exchange activity to circumvent the replicative helicase, which remains bound to the stalled fork. RAD51 is not required for fork reversal if the helicase is unloaded. Thus, we propose that RAD51 creates a parental DNA duplex behind the helicase that is used as a substrate by the DNA translocases for branch migration to create a reversed fork structure. Our data explain how fork reversal happens while maintaining the helicase in a position poised to restart DNA synthesis and complete genome duplication.